Immunogenicity, Safety, and Efficacy of Abatacept Administered Subcutaneously With or Without Background Methotrexate in Patients With Rheumatoid Arthritis: Results From a Phase III, International, Multicenter, Parallel-Arm, Open-Label Study

Abatacept in subjects who switch from intravenous to subcutaneous therapy: results from the phase IIIb ATTUNE study

(2012) Edward Clark Keystone et al.   ANNALS OF THE RHEUMATIC DISEASES

Evaluation of abatacept administered subcutaneously in adults with active rheumatoid arthritis: impact of withdrawal and reintroduction on immunogenicity, efficacy and safety (phase Iiib ALLOW study)

(2011) Jeffrey Kaine et al.   ANNALS OF THE RHEUMATIC DISEASES

Subcutaneous abatacept versus intravenous abatacept: A phase IIIb noninferiority study in patients with an inadequate response to methotrexate

(2011) M. C. Genovese et al.   ARTHRITIS AND RHEUMATISM

Immediate adverse reactions to biologicals: from pathogenic mechanisms to prophylactic management

(2011) Alessandra Vultaggio et al.   Current Opinion in Allergy and Clinical Immunology

Development of Antidrug Antibodies Against Adalimumab and Association With Disease Activity and Treatment Failure During Long-term Follow-up

(2011) Geertje M. Bartelds   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Predictors of response to methotrexate in early DMARD naive rheumatoid arthritis: results from the initial open-label phase of the SWEFOT trial

(2010) S. Saevarsdottir et al.   ANNALS OF THE RHEUMATIC DISEASES

Safety and Efficacy of the Selective Costimulation Modulator Abatacept in Patients with Rheumatoid Arthritis Receiving Background Methotrexate: A 5-year Extended Phase IIB Study

(2009) R. WESTHOVENS et al.   JOURNAL OF RHEUMATOLOGY

Cutaneous side effects of anti–tumor necrosis factor biologic therapy: A clinical review

(2009) Aikaterini-Evaggelia Moustou et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

The Simplified Disease Activity Index and Clinical Disease Activity Index to Monitor Patients in Standard Clinical Care

(2009) Daniel Aletaha et al.   RHEUMATIC DISEASE CLINICS OF NORTH AMERICA

Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis

(2008) T R D J Radstake et al.   ANNALS OF THE RHEUMATIC DISEASES

Results of a two-year followup study of patients with rheumatoid arthritis who received a combination of abatacept and methotrexate

(2008) Joel M. Kremer et al.   ARTHRITIS AND RHEUMATISM

Tumor necrosis factor alpha drugs in rheumatoid arthritis: systematic review and metaanalysis of efficacy and safety

(2008) Alberto Alonso-Ruiz et al.   BMC MUSCULOSKELETAL DISORDERS